Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis

SIMPLE SUMMARY: Myelofibrosis (MF) is a progressive myeloproliferative neoplasm with tendency towards leukemic transformation and has the poorest prognosis amongst the Philadelphia-negative classical myeloproliferative neoplasms (MPN). Ruxolitinib, the first FDA-approved JAK1/2 tyrosine kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Claudiani, Simone, Mason, Clinton C., Milojkovic, Dragana, Bianchi, Andrea, Pellegrini, Cristina, Di Marco, Antinisca, Fiol, Carme R., Robinson, Mark, Ponnusamy, Kanagaraju, Mokretar, Katya, Chowdhury, Avirup, Albert, Michael, Reid, Alistair G., Deininger, Michael W., Naresh, Kikkeri, Apperley, Jane F., Khorashad, Jamshid S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507927/
https://www.ncbi.nlm.nih.gov/pubmed/34638347
http://dx.doi.org/10.3390/cancers13194863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507927/
https://www.ncbi.nlm.nih.gov/pubmed/34638347
http://dx.doi.org/10.3390/cancers13194863

Ejemplares similares